CTOs on the Move

Emerging Health Information Technology

www.emerginghealthit.com

 
Emerging Health Information Technology is a Yonkers, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Innovative Labs

Innovative Labs (IL) is a leading developer, formulator, and provider of single serve and multi-dose ingestible health and wellness products for leading brands and direct sales companies.

Secure Doc Imaging

Secure Doc Imaging is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CDRG.ca (Canadian Disaster Restoration Group)

CDRG.ca (Canadian Disaster Restoration Group) is a Gloucester, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Chicago Institute for Psychoanalysis

The Chicago Institute for Psychoanalysis is a national leader in psychoanalytic education, scholarship and clinical services to the community. The Institute educates mental health professionals as adult and child psychoanalysts and psychotherapists in its Psychoanalytic Education Program, Adult Psychotherapy Program and Child and Adolescent Psychotherapy Program. Through its clinics, the Institute provides psychotherapy on a sliding scale to adults and children, serving some of Chicago`s most vulnerable and under served communities. It also offers community education programs and consultation to schools, courts, businesses and other organizations. Institute graduates and faculty are highly skilled practitioners of psychoanalysis and psychotherapy and are the teachers, supervisors and consultants to new generations of mental health practitioners.

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.